VOL. XCIV, NO. 247
WIDE MOAT STOCKS COMPARISON
Stock Comparison
Gilead Sciences, Inc. vs Pfizer Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted across the company's segments.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisPfizer Inc.
PFE · New York Stock Exchange
Weighted across the company's segments.
Comparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (76 / 100 vs 58 / 100 for Pfizer Inc.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (74.6% in HIV); Pfizer Inc. has 5 segments (37.5% in Primary Care).
- Moat breadth: Gilead Sciences, Inc. has 3 moat types across 3 domains; Pfizer Inc. has 1 across 1.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
74.6%
Pfizer Inc.
Primary Care
Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)
Global
Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement
Innovator biopharma (R&D + manufacturing + commercialization)
37.5%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
Pfizer Inc. strengths
No unique moat types yet.
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Pfizer Inc. segments
Full profile >Primary Care
Oligopoly
Specialty Care
Oligopoly
Oncology
Competitive
Hospital and Biosimilars
Competitive
Pfizer CentreOne
Competitive
Act on this comparison
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.